Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
193 Results for "
CSFs
" in MedChemExpress (MCE) Product Catalog:
Products (193)
193 Results for "CSFs" in MCE Product Catalog:
Cat. No.: HY-N9566
CAS No.: 64125-33-3
Target:
Cat. No.: HY-137863
CAS No.: 69372-19-6
Target:
Research Areas:
Pemirolast is an orally active antiallergic agent. Pemirolast attenuates Paclitaxel (HY-B0015) hypersensitivity reactions. Pemirolast can be used for bronchial asthma and conjunctivitis research - .
Cat. No.: HY-153893
CAS No.: 1251957-89-7
Target:
Research Areas:
Magmas-IN-1 (compound 9) is a small molecule Magmas inhibitor (SMMI). Magmas is mitochondria associated，granulocyte-macrophage colony stimulating factor signaling molecule，as well as a GM-CSF inducible gene in myeloid cells. Magmas-IN-1 inhibits Magmas and modulates mitochondrial function. Magmas-IN-1 also inhibits proliferation in yeast at 4 μM .
Cat. No.: HY-109190R
CAS No.: 1619931-27-9
Synonyms: GB002 (Standard); PK10571 (Standard)
Target:
Research Areas:
Seralutinib (Standard) is the analytical standard of Seralutinib (HY-109190). This product is intended for research and analytical applications. Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib also targets to CSF1R and c-KiT with IC50s of 8 nM and 14 nM, respectively. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension .
Cat. No.: HY-N15307
CAS No.: 38070-97-2
Target:
AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits wild type BRAF, V600E mutant BRAF and wild type CRAF, with IC50s of 79 nM, 38 nM and 68 nM, respectively. AZ304 also has significant effect on other kinases, such as p38 (IC50, 6 nM), CSF1R (IC50, 35 nM). Anti-tumor activity .
Target:
Research Areas:
ATUX-1215 is an activator of protein phosphatase 2A (PP2A). ATUX-1215 reduced the phosphorylation of ERK, p38, JNK, and Akt and the secretion of IL-12p70, GM-CSF, and IL1α in Bleomycin hydrochloride (HY-17565A)-treated animals. ATUX-1215 can slow the progression of lung fibrosis .
Cat. No.: HY-P99913
CAS No.: 1384099-30-2
Target:
Research Areas:
Cat. No.: HY-W438351
CAS No.: 75500-02-6
Target:
Research Areas:
1,3-Dibenzyl-5-fluorouracil is a chemical inhibitor of osteoclastogenesis. 1,3-Dibenzyl-5-fluorouracil inhibits the expression of osteoclast markers by downregulating the receptor activator of NF-κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) signaling pathways. 1,3-Dibenzyl-5-fluorouracil can be used in the study of metabolic bone diseases .
Cat. No.: HY-178714
Target:
Research Areas:
JNJ627 is a small molecule allosteric inhibitor of IL-17A with a KD of 92 nM. JNJ627 effectively inhibits the binding of IL-17A and IL-17RA, with an IC50 value of 16 nM. JNJ627 is capable of inhibiting the secretion of G-CSF (granulocyte colony-stimulating factor) caused by IL-17A stimulation. JNJ627 can be used for the study of autoimmune diseases (such as psoriasis) .
Cat. No.: HY-P1111A
Target:
Research Areas:
Cat. No.: HY-174366
CAS No.: 2256080-83-6
JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity .
Category:
Human Gut Microbiota Metabolites Polysaccharides Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides
Target:
Cat. No.: HY-P1111
CAS No.: 222018-18-0
Target:
Research Areas:
Cat. No.: HY-W001198
CAS No.: 16063-70-0
Research Areas:
2,3,5-Trichloropyridine is a trichloro-substituted pyridine derivative and also serves as an intermediate in the production of herbicidal active substances .
Cat. No.: HY-19772
CAS No.: 1018673-42-1
Synonyms: ESM-HDAC391; CHR-5154; HDAC-IN-3
Research Areas:
GSK3117391 (ESM-HDAC391; CHR-5154; HDAC-IN-3) is an orally active HDAC inhibitor with a IC50 of 55 nM. Using esterase-sensitive motif technology, GSK3117391 is selectively converted into its active acid metabolite HDAC189 in cells expressing carboxylesterase-1. GSK3117391 induces sustained global protein acetylation in monocytes, inhibits the production of proinflammatory cytokines, depletes circulating monocytes, downregulates the expression of CSF1R, and inhibits monocyte adhesion and differentiation. GSK3117391 can be used in the research of chronic inflammatory diseases .
Cat. No.: HY-187646
CAS No.: 2231259-57-5
Target:
Research Areas:
IACS-9439-Cl is a derivative of IACS-9439. IACS-9439 is an orally active and selective colony-stimulating factor 1 receptor (CSF1R) inhibitor with a Kd of 1 nM. IACS-9439-Cl reduces the population of tumor-associated macrophages. IACS-9439-Cl promotes the polarization of macrophages toward the M1 anti-tumor phenotype and decreases the M2 pro-tumor phenotype, thereby exerting a tumor growth inhibitory effect. IACS-9439-Cl can be used in cancer-related research .
Synonyms: Q702
Target:
Research Areas:
Adrixetinib (Q702) is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
Cat. No.: HY-16632
CAS No.: 1333990-84-3
Target:
Research Areas:
ELND 006 (Compound 30) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while sparing Notch signaling. It was developed through a synthetic strategy emphasizing diversity and chirality. ELND 006, along with its analog ELND007 (Compound 34), progressed into human clinical trials. In preclinical studies, both compounds demonstrated effective reduction of Aβ levels in vitro and in vivo. Comparisons with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat underscored their potency and specificity in lowering Aβ levels in cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic efficacy in Alzheimer's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
